MedTrace Logo

Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects

NCT06063291 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-11-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of ID110521156 in healthy adult subjects. This is the first clinical study of ID110521156.

Conditions

  • Healthy Adult Subjects

Interventions

DRUG

ID110521156

subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1

DRUG

Placebo of ID110521156

subjects will receive a single oral dose of IMP. In the morning (all procedures must be performed at the similar clock time) on Day 1

Sponsors & Collaborators

  • YUNOVIA CO.,LTD.

    collaborator UNKNOWN

  • IlDong Pharmaceutical Co Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-20
Primary Completion
2024-07-11
Completion
2024-07-11

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06063291 on ClinicalTrials.gov